drugset / Trial / NCT01810380

Brexpiprazole in Patients With Acute Schizophrenia

NCT01810380 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

To determine the efficacy and safety of brexpiprazole for the treatment of adults experiencing an acute episode of schizophrenia.

Timeline

Start
2013-03
Primary completion
2014-12
Completion
2014-12

Outcome

Missed primary endpoint

registry Placebo vs Brexpiprazole; p = 0.0560; Least square mean difference -4.1 (95% CI -8.2 to 0.1) NCT01810380 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Brexpiprazole Small molecule 2 mg —
Subject Brexpiprazole Small molecule 3 mg —
Subject Brexpiprazole Small molecule 4 mg —
Subject Quetiapine Small molecule 400 mg —
Subject Quetiapine Small molecule 600 mg —
Subject Quetiapine Small molecule 800 mg —

Indications